Navigation Links
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Date:10/8/2007

RARITAN, N.J., Oct. 8 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. today announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including some infections that were caused by methicillin-resistant Staphylococcus aureus (MRSA).

These data were presented at the 45th annual meeting of the Infectious Disease Society of America (IDSA) in San Diego, California. Ceftobiprole is licensed from, and is being co-developed with, Basilea Pharmaceutica Ltd.

Staphylococcus aureus is the predominant Gram-positive+ bacteria associated with many infections, including complicated skin and skin structure infections (cSSSI) and is carried by approximately 25-30% of the U.S. population. During the last 30 years, MRSA has become more prevalent as a cause of complicated skin and skin structure infections, including diabetic foot infections, which are particularly challenging to treat. In 1974, MRSA accounted for 2% of all Staphylococcus infections in the U.S. In 2004, this figure had risen to 63%.

According to the American Diabetes Association (ADA), nearly 21 million Americans suffer from diabetes. Diabetic foot infections can develop in the skin, muscle, or bones of the foot as a result of nerve damage and poor circulation associated with diabetes. A recent ADA study approximates that as many as 9% of Americans with diabetes will develop a diabetic foot infection, and that those who do develop such an infection are 55.7 times more likely to require hospitalization and 154.5 times more at risk of amputation.

Ceftobiprole belongs to a class of antibacterial agents known as cephalosporins, which are used to treat serious infections caused by Gram- negative++ and Gram-positive+ bacteria. In clinically evaluable patients, 500mg of ceftobiprole administered intravenously every eight hours (500mg IV q8h) demonst
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ay Someday Inform Treatments for Spinal Cord, Othe...ire-USNewswire/ -- A protein that enables,nerve ce...e in controlling,the developing nervous system. Re...ions to form among nerve cells may provide a basis...njuries to their nervous system,including spinal ...
(Date:10/8/2008)... program to evaluate TAXUS(R) Element(TM) Platinum...NATICK, Mass., Oct. 8 /- Bo...nounced that it has completed enrollment in,the PE...ird-generation,TAXUS(R) Element(TM) paclitaxel-elu...has enrolled nearly 1,500 patients at 100 U.S. and...
(Date:10/7/2008)...ct. 7 /- Prometheus Laboratories Inc....ced findings from its,development of PROMETHEUS(R)... irritable bowel syndrome (IBS). The findings sugg...rticular biomarkers in blood samples,between IBS a...iomarkers,combined with a proprietary algorithm, ...
(Date:10/7/2008)...LEXX Trial Presented at the Osteoarthritis Researc...RSIPPANY, N.J., Oct. 7 /- Ferring Pha...the FLEXX Trial of Osteoarthritis of the,Knee, sho...ighly pure,non-avian high molecular weight form of...ior to intra-articular saline (IA-saline) for the ...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Specific antagonism lowers blood pressure 63 1New prion protein discovered by Canadian scientists may offer insight into mad cow disease 58 1New prion protein discovered by Canadian scientists may offer insight into mad cow disease 58 2Preclinical study suggests organ transplant drug may aid in lupus fight 53 1Preclinical study suggests organ transplant drug may aid in lupus fight 53 2First biomarker discovered that predicts prostate cancer outcome 48 1First biomarker discovered that predicts prostate cancer outcome 48 2First biomarker discovered that predicts prostate cancer outcome 48 3First biomarker discovered that predicts prostate cancer outcome 48 4
... from the ASSERT Trial Presented at EULAR, BARCELO... Data,presented today at the European League Again...Rheumatology showed that patients with,ankylosing ...mab),over two years experienced significant improv...eated patients showed sustained,reductions in spin...
...sults Published in Cancer Research, TARRYTOWN, N.Y...,Corporation today announced the results of scient...MPC-6827) is effective in treating,multiple types ...hanism by which MPC-6827 exerts its effects, and (...proteins known to be involved,in cancer drug resis...
Other Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...ster that took place two decades ago, scientists h... not as harmful// as it is thought to be. This n...level of toleration or limit of radioactive exposu...sidered safe. This might stir up a debate over nuc...
...nt of $6 million for the Florida State University ...lexia in children.// The schedule involves unders.... The grant will fund the creation of a National ...linary Learning Disabilities Center at FSU. The ce...
...ve found that any kind of exercise will help to pr...Todd M. Manini, an exercise physiologist at the U....of reports out there saying that self-reported exe...ial. We wanted to see if just usual daily activity...
...ion called aortic dissection (a tear in the larges...//. His death brought the focus on this deadly dis... and genetic disorders. Now, researchers have publ... dissection, showing that 90 percent of patients w...
Other Medicine News:Health News:Research Fund for FSU to Eradicate Dyslexia 2Health News:Physical Activity of any kind to Prolong Life 2Health News:Aortic Dissection - A Deadly Condition 2Health News:Aortic Dissection - A Deadly Condition 3Health News:Aortic Dissection - A Deadly Condition 4
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: